Zoo Biology 19:393–403 (2000)
Tuberculosis in Elephants in North
Susan K. Mikota,1 R. Scott Larsen,2 and Richard J. Montali3*
1Audubon Center for Research of Endangered Species, New Orleans, Louisiana2Department of Clinical Sciences, College of Veterinary Medicine and Biomedical
Sciences, Colorado State University, Fort Collins, Colorado
3Department of Pathology, Smithsonian National Zoological Park, Washington, DC
Within the past 4 years, tuberculosis (TB) has emerged as a disease of concernin elephants. The population of elephants in North America is declining [Wiese,1997], and transmissible diseases such as TB may exacerbate this trend. Guide-lines for the Control of Tuberculosis in Elephants, which require the screeningof all elephants for TB, were instituted in 1997 [USDA, 1997; 2000]. BetweenAugust 1996 and May 2000, Mycobacterium tuberculosis
was isolated from 18of 539 elephants in North America, indicating an estimated prevalence of 3.3%.
Isolation of the TB orga nism by culture is the currently recommended test toestablish a diagnosis of TB; however, culture requires 8 weeks. Further researchis essential to validate other diagnostic tests and treatment protocols. Zoo Biol19:393–403, 2000.
Key words: Loxodonta africana; Elephas maximus; tuberculosis; bacterial disease
Tuberculosis (TB) was first described in elephants more than 2,000 years ago
by ancient Ayurvedic physicians in Ceylon [Iyer, 1937; McGaughey, 1961]. In re-cent times, a case in London [Garrod, 1875] was followed by sporadic reports through-out the twentieth century [Narayanan, 1925; Baldrey, 1930; Gutter, 1981; Saunders,1983; Chandrasekharan, et al., 1995]. Although it is thought that elephants are sus-ceptible to Mycobacterium bovis
[Dannenberg, 1978; Schmidt, 1986], Mycobacte-rium tuberculosis
) has been identified as the causative agent in allcases in which bacteria have been isolated. To date, most reported cases of TB haveoccurred in captive Asian elephants (Elephas maximus
). Two suspected cases in Af-
R.S. Larsen is currently at the Environmental Medicine Consortium, Department of Clinical Sciences,College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina.
*Correspondence to: Richard J. Montali, Department of Pathology, Smithsonian National ZoologicalPark, Washington, DC 20008-2598. E-mail: email@example.com
Received for publication December 1, 1999; Accepted June 20, 2000.
2000 Wiley-Liss, Inc.
Mikota et al.
rican elephants (Loxodonta africana
) in Uganda and Israel were not confirmed byculture [Woodford, 1982; Gorovitz, 1962]. M. tuberculosis
was isolated from an Af-rican elephant in France [Urbain, 1938]. In a retrospective medical study of 379elephants in North American zoos, eight elephants died of TB between 1908 and1994 [Mikota et al., 1994]. It is likely that this figure would have been higher hadprivately owned elephants been included in the survey.
RECENT CASES (1996–2000)
Between August 1996 and June 2000, samples from 539 elephants were sub-
mitted to the National Veterinary Services Laboratory (NVSL, Ames, IA) for myco-bacterial culture [J. Payeur, personal communication]. Seventeen elephants from eightherds in Illinois, California, Arkansas, Missouri, and Florida were diagnosed withTB. At the time of diagnosis, three elephants resided in American Zoo and AquariumAssociation accredited zoos and 14 in private facilities. There had been known pre-vious contact between elephants in five of the herds. Three elephants demonstratedclinical signs that could be caused by TB. M. tuberculosis
was isolated from 12elephants pre-mortem and five elephants post-mortem. Restriction fragment lengthpolymorphism was performed on M. tuberculosis
isolates from 11 elephants. Fivedistinct M. tuberculosis
strains were identified by this analysis [D.L. Whipple, 1997;personal communication].
Based on the 539 elephants in the NVSL database and the 532 elephants iden-
tified by the North American Regional Studbook keepers [M. Keele and D. Olson,personal communication], the prevalence of TB in elephants in North America isestimated to be 3.3%.
Confirmed cases of TB in elephants have typically been identified on post-
mortem examination as ante-mortem signs are frequently absent. Chronic weightloss, anorexia. and weakness may occur [McGaughey, 1961; Gutter, 1981; Saunders,1983], and dyspnea and coughing are sometimes observed [Seneviratna et al., 1966;Pinto et al., 1973]. Exercise intolerance is most likely to be observed in workinganimals [K.U. Mar, personal communication]. In Ceylon, ancient Ayurvedic elephantphysicians regarded ventral edema as a sign of incurable lung disease [Pinto et al.,1973]. More recently, ventral edema has been observed in some TB-infected elephants;however, it may have been caused by concurrent congestive heart failure, anemia, orother medical conditions [Seneviratna et al., 1966; Pinto et al., 1973].
Several techniques have been used to diagnose mammalian TB. Methods such as
culture, acid fast smears, fluorescent smears, and nucleic acid amplification techniquesdirectly detect the bacterial organism. Indirect methods such as serological assays, thegamma-interferon test (GIT), and the intra-dermal tuberculin test detect antigen-anti-body or cellular reactivity to mycobacterial antigen [Mikota and Maslow, 1997].
In humans and domestic animals, the intra-dermal tuberculin skin test is the
primary screening method to detect infection with M. tuberculosis
or M. bovis
Tuberculosis in Elephants
intra-dermal tuberculin test is the official ante-mortem test in cattle, bison, anddeer and is incorporated into the U.S. Department of Agriculture (USDA) eradica-tion guidelines [Essey and Davis, 1997; USDA, 1994; 1999]. The blood TB test(BTB), enzyme-linked immunosorbent assay (ELISA), and GIT have been used todiagnose TB infection in a limited number of species [Griffin and Cross, 1989;Rothel et al., 1992; Gaborick et al., 1996]. These indirect methods have not beenvalidated in most non-domestic species nor have they been uniformly administeredor consistently interpreted [Montali and Hirschel, 1990]. The limitations of apply-ing such diagnostic tests to non-domestic species have been discussed [Hietala andGardner, 1999].
Intra-dermal tuberculin testing is used in conjunction with slaughter surveil-
lance to control TB in domestic cattle [Thompson et al., 1998]. Obviously, this methodshould not be applied to species such as the elephant. The current gold standard forthe ante-mortem diagnosis of M. tuberculosis
infection in elephants is mycobacterialculture of respiratory secretions obtained by trunk “wash” [USDA, 1997; 2000]. El-ephants must be conditioned to permit the trunk wash procedure, which consists ofthe instillation of 60 mL of sterile saline into one or both nostrils, application of a 1-gal plastic bag over the end of the trunk, elevation of the trunk to distribute thesaline, and collection of a forcibly exhaled sample into the bag [Isaza and Ketz,1999]. Because the TB organism can be shed intermittently, three samples are col-lected on separate days.
To date, intra-dermal and serologic tests have frequently shown poor correla-
tion with mycobacterial culture results in elephants [Montali et al., 1998]. One el-ephant that died from disseminated pulmonary M. tuberculosis
infection had negativeresults when tested with human and bovine purified protein derivative (BPPD) tu-berculins [Saunders, 1983]. Furthermore, four of five M. tuberculosis
culture-posi-tive elephants diagnosed since 1996 have demonstrated negative intra-dermaltuberculin responses to BPPD or balanced tuberculins. Eight of 30 M. tuberculosis
culture-negative elephants had suspect tuberculin responses [Mikota, 1999].
Nucleic acid amplification techniques (NAAT) such as PCR detect mycobacte-
ria by amplification of DNA or RNA [de Wit et al., 1990; Clarridge et al., 1993;Liébana et al., 1995; Roberts et al., 1996]. Advantages of NAAT include rapid turn-around time (hours) and the capability of detecting low numbers of organisms. Thesetechniques have been reported to have high specificity for M. tuberculosis complex
organisms (M. tuberculosis, M. bovis, M. africanum, M. microti
), but mycobacterialspecies cannot be differentiated. Since both live and dead organisms are detected,NAAT is of limited value in monitoring response to therapy.
There are at present two amplification assays that are approved by the U.S. Food
and Drug Administration for commercial use in human clinical and public health labo-ratories: the Amplicor MTB PCR (Roche Molecular Systems, Branchburg, NJ) and theAmplified M. tuberculosis
Direct Test (MTD ) (Gen-Probe, San Diego, CA). Theseassays have demonstrated specificities of ≥95%, but they have been less sensitive thanculture for diagnosis of M. tuberculosis
in humans [Dalovisio et al., 1996].
Validation has not yet been reported in elephants. Between August 1996 and August1999, the NVSL performed the MTD on 612 elephant samples. The MTD correctlydiagnosed six of nine culture-positive samples and 559 of 581 culture-negative samples.
Results of 23 samples were inconclusive [J. Payeur, personal communication]. Usingculture as the gold standard, the MTD demonstrated a sensitivity of 66.6% and a speci-
Mikota et al.
ficity of 96.2%. Validation of this test is still needed, and, at this time, the MTD andother NAATs are considered ancillary tests for detecting TB in elephants.
Serologic testing for TB has been performed using ELISA techniques with a
non-species–specific protein A that is labeled with horseradish peroxidase. Early in-vestigation of this technique in a herd of five elephants, which included one culture-positive animal, was described by Thoen and colleagues . The antigens usedwere heat-killed cells of M. bovis,
BPPD, and purified protein derivative of M. avium
Two tuberculin-test positive elephants showed substantial seroreactivity toheat-killed M. bovis
and BPPD, whereas two of three tuberculin-test negative ani-mals showed seroreactivity only to heat-killed M. bovis.
Between 1997 and 1998, during the evaluation of a herd of four culture-nega-
tive elephants, it was proposed that tuberculin exposure may influence serologic andBTB analysis [Montali et al., 1998]. The antigens used in this serologic investigationwere BPPD, M. tuberculosis
culture filtrate protein, M. avium
culture filtrate protein,APPD, and a lipoarabinomannan antigen (LAM) derived from M. tuberculosis
. El-ephants showed minimal to zero reactivity to these antigens before intra-dermal tu-berculin injection, but dramatic increases in seroreactivity after injection. Elephantsare constantly exposed to saprophytic Mycobacterium
species and can be colonizedby non-tuberculous mycobacteria (as well as M. avium
) due to their behavior ofbathing and dusting using their trunks. These organisms do not appear to cause clini-cal disease, but it has been hypothesized that such exposure accounts for these seem-ingly non-specific reactions to mycobacterial antigens [Montali et al., 1998].
Recently, a multiple-antigen ELISA was evaluated for its ability to detect M .
infection in captive elephants [Larsen et al., 2000]. Serum samples werecollected from 32 Asian and 15 African elephants, and a panel of six antigens wasused to determine seroreactivity. The antigens included M. bovis
culture filtrate (CF),PPD, M. bovis
modified protein 70, two LAM antigens from strains of M. tuberculo-sis
, and APPD. Discriminant analysis was used to determine the linear combinationof antigens that accurately predicted the true infection status of the most animals,and the resulting classification functions were used to calculate the percentage ofanimals that were correctly classified. Of 47 elephants, seven of the Asians wereinfected (culture-positive); 25 Asians and 15 Africans were considered non-infected(culture-negative). Criteria for elephants designated as non-infected were: 1) trunkwashes within 4 months of serum sampling that were negative for mycobacterialculture of M. tuberculosis
or M. bovis
; 2) no contact with elephants or other animalsthat had been diagnosed with M. tuberculosis
of M. bovis
within the past 5 years; 3)no intra-dermal tuberculin testing within the 6 months before sampling; and 4) notravel outside the institution in the previous 5 years. The specificity and sensitivityof the multiple-antigen ELISA, with 95% confidence intervals, were 100% (91.9–100%) and 100% (54.4–00%), respectively. The limitations inherent to this studysuggest that much additional research is needed regarding the use of this ELISA;however, the results also indicate that this multiple-antigen ELISA may be a goodscreening test for elephants [Larsen et al., 2000].
The major pathology in elephants infected with M. tuberculosis
curs primarily in the lungs and thoracic lymph nodes with lesser involvement of
Tuberculosis in Elephants
extra-thoracic sites [Seneviratna et al., 1966; Pinto et al., 1973, Gutter 1981; Saunders1983; Michalak et al., 1998; R.J. Montali, unpublished observations, 1999]. As inother animals, tubercular lesions in elephants appear to vary with the staging of thedisease. In the less extensive cases, firm granulomatous nodules, sometimes withcaseous foci, are noted in the bronchial lymph nodes and pulmonary tissue. Elephantswith extensive involvement of both lungs (≥66%) usually die with severe caseo-calcareous and cavitating lesions. These often result in large pulmonary abscessesfrom which M. tuberculosis
and opportunistic bacteria such as Pseudomonasaeruginosa
have been isolated. Tenacious, mucopurulent, bronchial plugs are alsocommon in advanced TB; bronchial and other thoracic lymph nodes are markedlyenlarged and usually show a proliferative response with less caseation than the pul-monary lesions.
The pathologic descriptions “caseous” and “mucopurulent” are based on post-
mortem observations of the lungs and upper respiratory tract. At post-mortem, theseverity of the disease is determined and a time frame ascribed. Active, early lesions,which conceivably can occur within weeks to months, are usually localized and lim-ited in size and scope. Advanced lesions may involve major portions of one or bothlung lobes and become mineralized over a period of months to years. Both, however,may have areas that are caseous or mucopurulent.
Characteristic histologic findings include epithelioid granulomas with some gi-
ant cell formation in the earlier lymph node and pulmonary lesions and extensivecaseous and pyogranulomatous pneumonia in the advanced forms. Though sparse,acid-fast bacilli are more easily found in central areas of caseation in the lungs butare typically rare in the lymph nodes.
Bronchial and tracheal tuberculous plaques and caseous and mucopurulent exu-
date in the nasal passages have been noted in both the early and late stages of TB,suggesting that the shedding of mycobacteria may occur at any stage of the disease.
Less extensive tuberculous lesions were observed in the mesenteric lymph nodes,liver, kidneys, adrenals, and spleen in some of the more advanced cases. These le-sions suggest that in disseminated cases shedding may occur by routes other than therespiratory system.
There is little information in the literature regarding treatment of elephants for
TB. In one report, an Asian elephant was treated prophylactically with isoniazid (INH)after a suspect intradermal tuberculin test [Devine et al., 1983]. Another suspectedcase of TB was treated with streptomycin administered intramuscularly on alternatedays for 4 weeks [Chandrasekharan et al., 1995]. Current treatment protocols havebeen extrapolated from human treatment regimens [American Thoracic Society, 1994]and are still under investigation for efficacy in elephants.
Anti-TB drugs recently used in elephants includes INH, pyrazinamide (PZA),
rifampin (RIF), and ethambutol (ETH). These drugs have been administered to elephantsin food, by direct oral administration, and rectally. Oral delivery has been challenging,as many elephants refuse oral medications. Direct oral administration can be achievedin some elephants by conditioning the animals to accept a bite block and oral syringe[L. Peddie and J. Peddie, personal communication]. For other elephants, rectal drugadministration techniques (including suppositories) have been developed.
Mikota et al.
Blood levels of INH, consistent with human therapeutic values, can be achieved
in elephants by direct oral or rectal administration. Blood levels of RIF can be achievedorally, but not rectally [Dunker and Rudovsky, 1998]. PZA appears to be absorbedby either route [S.K. Mikota, unpublished data]. When anti-TB drugs are adminis-tered in food, blood levels are variable and this route of administration is not recom-mended. Anti-TB drug doses for individual elephants should be determined bymeasuring blood-level response. Elephants should be weighed before and through-out treatment.
The current recommended treatment for known infected elephants consists
of INH and RIF daily for 2 months, then every other day for 10 months. A thirddrug, such as PZA, is given daily for the first 2 months of treatment. As a start-ing dose, INH can be given orally or rectally at a dose of 2.5–5.0 mg/kg. Al-though humans typically achieve a blood level of 3–5 µg/mL of INH at 2 hours[C.A. Peloquin, personal communication], some elephants became ill when theirblood levels were in this range. An INH blood level of 1–2 µg/mL is recom-mended for elephants.
RIF can be initiated orally at a dose of 7.5–10.0 mg/kg orally. Human 2-hour
blood levels for this drug are 8–24 µg/mL. PZA can be initiated at a dose of 25–35mg/kg orally or rectally. Human 2-hour levels for PZA are 20–60 µg/mL. Supple-mentation with vitamin B6 (pyridoxine) at a daily dose of 1 mg/kg is recommendedto prevent possible peripheral neuropathy, a condition that has been associated withINH therapy in humans [Goldman and Braman, 1972].
Side effects of treatment may include anorexia, lethargy, and colitis. Leukope-
nia was observed in one elephant receiving INH and RIF; the condition resolvedafter treatment was temporarily stopped and dosages adjusted [L. Peddie and J. Peddie,personal communication]. Elevations of liver enzymes have been observed in asso-ciation with INH toxicity in humans and elephants.
Of 11 living M. tuberculosis
culture-positive elephants, six are currently re-
ceiving anti-TB drugs including one elephant that is undergoing a second course oftreatment. Five elephants that completed treatment in December 1997, June 1998,December 1998, October 1999, and April 2000, are presently culture negative. Allculture-positive elephants ceased shedding organisms shortly after treatment was ini-tiated and remained culture-negative during the treatment period.
GUIDELINES FOR THE CONTROL OF TB IN ELEPHANTS
In 1996, in response to the TB-related deaths of two privately owned el-
ephants, an Elephant Tuberculosis Advisory Panel was formed. This panel, whichwas composed of USDA and zoo veterinarians, cooperated with the National Tu-berculosis Working Group for Zoo and Wildlife Species to develop Guidelines forthe Control of Tuberculosis in Elephants
[USDA, 1997; 2000; www.aphis.usda.gov/ac/acindex.html]. These guidelines specify criteria for the testing, surveillance, andtreatment of elephants for TB. In January 1998 and January 2000, they weredistributed by the Animal Care Division of the USDA Animal Plant Health In-spection Service (USDA-APHIS) to all licensed elephant exhibitors regulated bythe Animal Welfare Act. The guidelines require annual testing (three trunk cul-tures) of all elephants and strongly recommend submission of samples for ancil-lary diagnostic tests.
Tuberculosis in Elephants
According to the guidelines, elephants are placed in one of four groups based
on culture results and exposure history. Group A elephants have negative cultureresults and no known exposure to a culture-positive animal in the previous 5 years.
These animals are cultured annually and have no travel restrictions while they re-main culture negative for M. tuberculosis.
Culture-negative elephants exposed to aculture-positive animal 1–5 years previously (group B) are cultured quarterly andhave no travel restrictions. Culture-negative elephants exposed to a culture-posi-tive animal within the previous 12 months (group C) may be monitored by culture(three-sample method), every other month for 1 year, with no travel permitted or,alternatively, may be treated, with travel permitted after 2 months if cultures re-main negative. Culture-positive elephants (group D) are not permitted to traveluntil at least 6 months of treatment have been completed and two negative cultureshave been demonstrated. Figure 1 illustrates the sequence of events for each of thefour groups.
A thorough post-mortem examination should be performed on all elephants that
die or are euthanized. Lungs and lymph should be closely examined for evidence ofTB. Cultures for TB should be submitted on all elephants even if gross lesions areabsent. A necropsy protocol for elephants may be accessed at the above website.
IMPLICATIONS FOR HUMAN HEALTH
After the diagnosis of TB in the Illinois herd, all personnel were tuberculin
tested by the Illinois Department of Health. Of 22 handlers, 11 were tuberculin testpositive. Eight of the 11 were positive on the initial test, indicating the possibility ofprior exposure; three individuals converted during the investigation. One handlerhad culture-positive TB. The isolate from this individual matched that of the Illinoiselephants [Michalak et al., 1998]. The original source of infection (for both elephantsand humans) is unknown.
The apparent low incidence of TB in African elephants and the absence of
reports of TB in free-ranging elephants suggest that this is primarily a disease ofhumans and that elephants are accidental hosts. Nonetheless, M. tuberculosis
can betransmitted between elephants and humans and must be considered zoonotic [Maslow,1997; Michalak et al., 1998]. Humans are most likely to contract TB when they haveprolonged contact with infected individuals. It is likely that this is also the case withelephants, suggesting that handlers with close, daily contact with infected animalsare at greatest risk. Elephant handlers and other personnel in contact with elephantsshould be tested for TB annually following established human testing protocols. Allnew employees should be tested before contact with elephants and anyone with ac-tive TB should not have contact with elephants. Some zoos have developed elephant/people interaction protocols to limit direct visitor contact with elephants, a practicethat should be encouraged [Montali, 1999].
The ante-mortem diagnosis of TB in elephants continues to be problematic.
Although identification of M. tuberculosis
definitively establishes the presence ofinfection, failure to isolate the organism does not rule out infection. Mycobacteriaare slow-growing organisms and culture typically requires 8 weeks. Clearly, better
Mikota et al.
Elephant management groups for TB surveillance [from USDA, 2000]. (For protocol, see Guidelines for the Control of Tuberculosis in El-
ephants [USDA, 2000] www.aphis.usda.gov/ac/acindex.html).
Tuberculosis in Elephants
diagnostic tests are needed. Preliminary ELISA results are promising, but many moresamples (both culture positive and negative) must be analyzed before this test (orany other serologic test) can be validated. Institutions holding elephants are stronglyencouraged to submit samples for ancillary diagnostic tests so that valuable researchdata may be collected.
Although there is optimism that infected elephants in the North American popu-
lation have been successfully treated, only long-term monitoring will confirm this.
Pharmacokinetic studies are needed to further evaluate anti-TB drugs and to validatetherapeutic protocols. It is essential that elephants that undergo treatment be observedfor possible side effects. Blood levels of anti-TB drugs must be documented andcorrelated with treatment outcome.
Information on the pathophysiology and staging of TB in elephants is needed.
A necropsy should be performed on all elephants that die and a thorough search forTB lesions should be conducted, even if the disease is not suspected. The elephantnecropsy protocol (available on the USDA website) outlines appropriate samples tosubmit for laboratory evaluation. In cases of euthanasia, a diagnostic workup for TB(including ancillary tests as outlined in the guidelines) should be performed pre-mortem so that results can be correlated with postmortem findings.
A reporting mechanism has been established whereby annual culture and ancil-
lary test results are submitted to the American Association of Zoo Veterinarians fortabulation. Compliance has been poor for this critically needed information. We en-courage the cooperation of the zoo community to comply with this reporting mecha-nism so that we may further our understanding of TB in elephants.
1. Reported cases of TB in elephants have been caused by M. tuberculosis
(the agent of human TB). Although TB has been reported more frequently in Asianelephants, it is unknown whether there is a true species predilection.
2. Isolation of M. avium
and non-tuberculous mycobacteria from elephant trunk
wash samples is common, but these organisms have not been associated with clinicaldisease.
3. Isolation of M. tuberculosis
is currently the only definitive test to diagnose
TB in elephants, although ancillary tests such as NAAT and ELISA may be useful.
4. The intra-dermal tuberculin test is unreliable for diagnosing TB in elephants.
5. It is possible to deliver dosages of anti-TB drugs that achieve blood levels
consistent with therapeutic levels in humans; however, the long-term efficacy of cur-rent treatment protocols remains to be documented.
6. Shedding of TB organisms generally ceases when elephants receive ad-
7. Transmission of TB between an elephant and a human has been reported.
Handlers in close daily contact with infected elephants are at greatest risk.
8. Elephants may be at risk of contracting TB from infected humans. Han-
dlers should undergo periodic TB screening to minimize risks to elephant health.
9. Complete post-mortem examination should be performed on all elephants
that die. A thorough search for TB lesions should be conducted even if TB is notsuspected.
10. Zoos are encouraged to establish protocols for elephant-visitor interactions.
Mikota et al.
Many individuals have been involved in addressing the complex issues associ-
ated with TB in elephants. We acknowledge the following individuals who have con-tributed to our knowledge of the epidemiology, diagnosis, and treatment of this diseasein elephants: Joel Maslow, M.D. Ph.D., Freeland Dunker, D.V.M., Gary West, D.V.M.,Ramiro Isaza, D.V.M., William Lindsay, D.V.M., Jim Peddie, D.V.M., Linda Peddie,D.V.M., Wilbur Amand, V.M.D., Mitch Essey, D.V.M., Werner Heuschele, D.V.M.,Janet Payeur, D.V.M., Diana Whipple, Miava Binkley, D.V.M., Delphi Chatterjee,Ph.D., Mo Salman, B.V.M.S., Ph.D., Scott and Heidi Riddle, Gary and Kari Johnson,John Cuneo, and the dedicated elephant handlers who have been involved with thetreatment of infected elephants.
American Thoracic Society. 1994. Treatment of tu-
Wildlife Veterinarians Joint Conference. Omaha,
berculosis and tuberculosis infection in adults and
children. Am J Respir Crit Care Med 149:359–74.
Essey MA, Davis JP. 1997. Status of the national
Baldrey FSH. 1930. Tuberculosis in an elephant. J
cooperative state-federal bovine tuberculosis
eradication program fiscal year 1997. Proceedings
Chandrasekharan K, Radhakrishnan K, Cheeran JV,
of the One Hundred and First Annual Meeting of
Muraleedharan Nair KN, Prabhakaran T. 1995.
the United States Animal Health Association. Lou-
Review of the incidence, etiology and control of
common diseases of Asian elephants with spe-
Gaborick CM, Salman MD, Ellis RP, Triantis J.
cial reference to Kerala. A week with elephants.
1996. Evaluation of a five-antigen ELISA for di-
Proceedings of the International Seminar on the
agnosis of tuberculosis in cattle and Cervidae. J
Conservation of the Asian Elephant (June 1993).
Bombay Natural History Society, Bombay: Ox-
Garrod AH. 1875. Report on the Indian elephant
which died in the society’s gardens on July 7,
Clarridge JE, Shawar RM, Shinnick TM, Plikaytis
1875. Proceedings Zoological Society of London.
BB. 1993. Large-scale use of polymerase chain
reaction for detection of Mycobacterium tuber-
Goldman AL, Braman MAJ.1972. Isoniazid: A re-
in a routine mycobacteriology laboratory.
view with emphasis on adverse effects. Chest
Dalovisio JR, Montenegro-James S, Kemmerly SA,
Gorovitz C. 1962. Tuberculosis in an African El-
Genre CF, Chambers R, Greer D, Pankey GA,
Failla DM, Haydel KG, Hutchinson L, Lindley
Griffin JF, Cross JP. 1989. Diagnosis of tuberculo-
MF, Nunez BM, Praba A, Eisenach KD, Copper
sis in New Zealand farmed deer: an evaluation of
ES. 1996. Comparison of the amplified Mycobac-
intradermal skin testing and laboratory techniques.
(MTB) direct test, Amplicor
Gutter A. 1981. Mycobacterium tuberculosis
MTB in respiratory specimens. Clin Infect Dis
Asian elephant. Proceedings of the American As-
of Zoo Veterinarians.
Seattle, WA. p
Dannenberg AM. 1978. Pathogenesis of tuberculo-
sis in man and animals: protection of personnel
Hietala SK, Gardner IA. 1999. Validity of us-
against tuberculosis. In: Montali RJ, editor. My-
ing diagnostic tests that are approved for use
cobacterial infections of zoo animals. Washing-
in domestic animals for nondomestic species.
ton, DC: Smithsonian Institution Press. p 65–75.
In: Fowler, ME, editor. Zoo and wild animal
de Wit D, Steyn L, Shoemaker S, Sogin M. 1990.
medicine, 4th ed. Philadelphia: WB Saunders.
Direct detection of Mycobacterium tuberculosis
in clinical specimens by DNA amplification. J
Isaza R, Ketz CJ. 1999. A trunk wash technique
for the diagnosis of tuberculosis in elephants.
Devine JE, Boever WJ, Miller E. 1983. Isoniazid
Verhandlungsbericht des Internationalen Sympo-
therapy in an Asiatic elephant (Elephas maximus
siums uber die Erkrankungen der Zootiere,
Dunker F, Rudovsky M. 1998. Management and
Iyer AK. 1937. Veterinary science in India, ancient
treatment of a Mycobacterium tuberculosis
and modern with special reference to tuberculo-
positive elephant at the San Francisco Zoo. Pro-
sis. Ag Lvstk India
ceedings of the American Association of Zoo
Larsen RS, Salman MD, Mikota SK, Isaza R,
Veterinarians and the American Association of
Montali RJ, Triantis J. Evaluation of a multiple-
Tuberculosis in Elephants
antigen enzyme-linked immunosorbent assay for
Tuberculosis in a domesticated Asiatic elephant,
detection of Mycobacterium tuberculosis
. Vet Rec 93:662–4.
tive elephants. J Zoo Wild Med (in press).
Rothel JS, Jones SL, Corner LA, Cox JC, Wood
Liébana E, Aranaz A, Mateos A, Vilafranca M,
PR. 1992. The gamma-interferon assay for diag-
nosis of bovine tuberculosis in cattle: conditions
Suarez G, Domingo M, Domingez L. 1995.
affecting the production of gamma-interferon in
Simple and rapid detection of Mycobacterium tu-
complex organisms in bovine tissue
Roberts GD, Böttger EC, Stockman L. 1996. Meth-
samples by PCR. J Clin Microbiol 33:33–6.
ods for the rapid identification of mycobacterial
Maslow J. 1997. Tuberculosis and other mycobacte-
ria as zoonoses. Proceedings of the American Asso-
Saunders G. 1983. Pulmonary Mycobacterium tu-
ciation of Zoo Veterinarians, Houston, TX. p 110–4.
infection in a circus elephant. J Am
McGaughey CA. 1961. Diseases of elephants. part
Schmidt MJ. 1986. Elephants. In: Fowler, ME, edi-
Michalak K, Austin C, Diesel S, Bacon JM, Zimm-
tor. Zoo and wild animal medicine, 2nd ed. Phila-
erman P, Maslow JN. 1998. Mycobacterium
delphia: W.B. Saunders. p 883–923.
infection as a zoonotic disease: trans-
Seneviratna P, de S Wettimuny SG, Seneviratna D.
mission between humans and elephants. Emerg
1966. Fatal tuberculosis in an elephant. Vet Med
Mikota SK, Sargent EL, and Ranglack GS. 1994.
Thoen CO, Mills K, Hopkins MP. 1980. Enzyme-
Medical management of the elephant. Bloomfield,
linked protein A: an enzyme-linked immunosorbent
assay reagent for detecting antibodies in tubercu-
Mikota SK, Maslow J. 1997. Theoretical and tech-
lous exotic animals. Am J Vet Res 41:833–5.
nical aspects of diagnostic techniques for mam-
Urbain A. 1938. L’infection tuberculeuse spontanee
malian tuberculosis. Proceedings of the American
chez les mammiferes sauvages en captivite. Ann
Association of Zoo Veterinarians. Houston, TX.
United States Department of Agriculture, Animal
Mikota S. 1999. A review of diseases of the el-
and Plant Health Inspection Service 91-45-005.
ephant. Verhandlungsbericht des Internationalen
1994. Tuberculosis eradication in Cervidae uni-
Symposiums uber die Erkrankungen der Zootiere,
form methods and rules, effective May 15, 1994.
Mikota SK, Peddie L, Peddie J, Isaza R, Dunker F,
United States Department of Agriculture, Animal
and Plant Health Inspection Service, Animal Care.
Chatterjee D, Payeur J, Whipple D, Thoen C, Davis
1997. Guidelines for the control of tuberculosis
DS, Montali RJ, Maslow J. Epidemiology and di-
agnosis of Mycobacterium tuberculosis
United States Department of Agriculture, Animal and
groups of elephants. J Zoo Wild Med (in press).
Plant Health Inspection Service, 91-45-011. 1999.
Montali RJ, Hirschel PG. 1990. Survey of tubercu-
Bovine tuberculosis eradication uniform methods
lin testing practices at zoos. Proceedings of the
and rules, January 22, 1999. Washington, DC.
American Association of ZooVeterinarians. South
United States Department of Agriculture, Animal
and Plant Health Inspection Service, Animal Care.
Montali RJ, Spelman LH, Cambre RC, Chatterjee D,
2000. Guidelines for the Control of Tuberculosis
Mikota SK. 1998. Factors influencing interpretation
in Elephants. www. aphis.usda.gov/ac/acindex.html
of indirect testing methods for tuberculosis in el-
Wiese R. 1997. Demographic analysis of the Asian
Proceedings of the American Association
elephant population in North America. Proceed-ings of the Elephant Managers Association Work-
of Zoo Veterinarians and the American Association
of Wildlife Veterinarians. Omaha, NE. p 109–12.
Whipple DL. 1997. Molecular epidemiology of tu-
Montali RJ. Important aspects of zoonotic diseases
berculosis in wild white-tailed deer in Michigan
in zoo and wildlife species. 1999. Verhandlungs-
and elephants. Proceeding One Hundred and First
bericht des Internationalen Symposiums uber die
Annual Meeting of the United States Animal
Erkrankungen der Zootiere, Vienna. p 149–55.
Narayanan RS. 1925. A case of tuberculosis in an
Woodford MH. 1982. Tuberculosis in wildlife in
elephant. J Comp Pathol
the Ruwenzori National Park, Uganda (part II).
Pinto MRM, Jainudeen MR, Panabokke RG. 1973.
Schmerzmittel Die Sucht und ihre Stoffe Schmerzmittel: Opiate und Opioide Opiate und Opioide sind sehr stark wir-kende Schmerz- und Betäubungsmittel miteinem hohen Suchtpotenzial. Währendes sich bei Opiaten im engeren Sinne umjene Mittel handelt, die Opium oder Opi-umalkaloide – insbesondere Morphin –enthalten, bezeichnet der Begriff Opioi-de alle morphinähnlich wirken
R E I N E S P R O G E S T E R O N und G E S T A G E N E Univ. Prof. Dr. Doris M. Gruber und Univ. Prof. DDr. Johannes C. Huber Universitätsklinik für Frauenheilkunde Abteilung für Gynäkologische Endokrinologie und Reproduktionsmedizin Währinger Gürtel 18 –20 A-1090 Wien email: firstname.lastname@example.org www.frauenaerztin-gruber.at Ordination Wiedner Hauptstraße 95/6 A-1050